PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma Leukemia (2007) Phosphatidylinositol 3 kinases (PI3Ks) are important regulators of cellular growth, transformation, adhesion, apoptosis, survival and motility. 1 The activation of PI3K results in the generation of the second messenger, phosphatidylinositol 3,4,5 trisphosphate (PIP3) from phosphatidylinositol 4,5 bisphosphate (PIP2). PIP3 acts as an important second messenger lipid in tumorigenesis, by activating AKT and other pathways which inhibit apoptosis and promote cellular growth, proliferation, cell motility, angiogenesis whereas phosphatase and tensin homolog deleted on chromosome 10 (PTEN) catalyzes the precise opposite reaction, thereby reducing the pool of PIP3, inhibiting growth signals and suppressing tumor formation. One of the catalytic subunits of PI3K, the p110 catalytic subunit-a (PIK3CA), is a transforming oncogene, 2 that was shown to have activating mutations in the commonly occurring cancers. 3 Functional analysis of the common-hot spot PIK3CA mutations that have been done previously by performing experiments of overexpression as well as gene deletion using somatic cell knockouts, has demonstrated that these mutations are in fact oncogenic. 2 The constitutive activation of the PI3K/AKT signaling pathway in a subset of mantle cell lymphoma that includes blastoid variants, 4 and our recent findings of aberrant activation of the PI3K/AKT pathway in diffuse large B-cell lymphoma (DLBCL) have prompted us to study PTEN/PI3K/AKT pathway in the development and progression of DLBCL. 5 We investigated in this study the existence of PIK3CA mutation in 215 DLBCL, immunohistochemical expression of PTEN and p-AKT, and described for the first time the significant correlation of PIK3CA mutations to clinical markers and its relationship to functional PTEN.
To ensure a more complete understanding of PTEN/PI3K/AKT pathway in DLBCL, we performed mutational analysis of PIK3CA in a set of 215 DLBCL cases, obtained from King Faisal Specialist Hospital & Research Centre (KFSHRC) and a panel of 5 DLBCL cell lines (SUDHL4, SUDHL5, SUDHL8, SUDHL10 and OCI-LY19). Study approval was obtained from the Research Advisory Council (RAC no. 2030 019) at KFSHRC. PIK3CA sequence analysis was performed to assess the two hot-spot regions (exons 9 and 20), where more than 80% of the reported mutations reside.
3 PIK3CA mutations were identified in 17 of 215 (8%, Table 1 ) DLBCL and no mutations were found in all five DLBCL cell lines. We found two mutations in exon 9 (corresponding to the accessory domain of PIK3CA) and 15 mutations in exon 20 (corresponding to catalytic domain of PIK3CA). This indicates a predominance of exon 20 mutations in DLBCL tumors which is similar to what was reported earlier in breast cancer. 6 In our study, most of PIK3CA mutations were found mainly in the kinase domain (11 missense mutations were detected at codon 1047, Figure 1 ). In addition, four novel nucleic acid substitutions resulting in missense mutations, at codons 1007, 1026, 1040 and 1045 were discovered in our analysis (Table 1) . Meanwhile, only two mutations were found in exon 9, particularly at codons 543 and 545. Next, PTEN protein expression was investigated by immunohistochemistry (IHC) on these 215 DLBCL samples using tissue microarray technology. Out of which, 76 DLBCL samples (37%) showed reduced or loss of PTEN expression (PTEN À ). Correlation analysis between PIK3CA mutations and PTEN IHC status revealed a significant association, in that the majority of PIK3CA mutations were found in PTEN þ cases (P ¼ 0.0146), in concordance with an earlier report. 6 This probably implies that de-regulated PIP3 is critical for lymphomagnesis in a significant fraction of DLBCL and that loss of PIP3 homeostasis by abrogation of either PIK3CA or PTEN relieves selective pressure for targeting other genes, similar observations were made by other authors. 6, 7 Furthermore, 17 cases with PIK3CA mutations were screened for PTEN mutations. All nine exons of PTEN were sequenced and none of the DLBCL cases harboring PIK3CA mutations contained PTEN mutations. Although some recent studies have reported existence of double mutants for PIK3CA and PTEN in some tumors, our data excludes the possibility of coexistence of PTEN mutation with PIK3CA mutation as reported by Broderick et al., 7 who analyzed PIK3CA mutations in high-grade brain tumors. This might indicate that PIK3CA mutation is a potent activator of PI3K pathway by itself.
We were interested in testing the relationship between PIK3CA mutational status and other known clinicopathological markers. Clinical parameters like stage, extra nodal lesions and Mutations not previously reported. IPI were available only in 116/215 samples analyzed. PIK3CA mutations were associated with a higher IPI score although this was not statistically significant (P ¼ 0.0834), which might be attributed to the relatively small number of DLBCL cases that were positive for the PIK3CA mutation. In addition, it was significantly associated with involvement of more than one extra nodal site (P ¼ 0.0497) and with tumor stage (P ¼ 0.0103). As a read out of PIK3CA functional activation, we tested AKT phosphorylation in DLBCL by IHC. Virtually all of the samples harboring PIK3CA mutations showed some staining (scored þ 1 to þ 3) for p-AKT (17 out of the 17 cases). However, only 10 of the 17 (59%) mutated cases showed increased p-AKT level by IHC (defined as DLBC samples scored as þ 2 or þ 3). 5 Furthermore, our findings that PIK3CA mutations correlate with tumor stage, suggest that increased PIP3 production and activation of PI3K/AKT may enhance tumor progression. PIK3CA mutations showed association with the non-germinal-activated B-cell type subtype, although this association was not statistically significant (P ¼ 0.074).
Given the significant association of PIK3CA mutations to two clinical markers (tumor stage and involvement of more than one extra nodal site) we performed survival analysis. No significant associations were found between PIK3CA mutational status and overall survival within DLBCL patients. We further stratified all our DLBCL cases into two groups depending on the presence of PIK3CA mutation and PTEN expression status: normal PIK3CA and normal PTEN (n ¼ 114) and DLBCL with either mutated PIK3CA or absent/reduced PTEN expression (n ¼ 91). Such a stratification showed a significant correlation with 10-year overall survival (P ¼ 0.0249) and remained significant even in multivariate analysis that included IPI, stage, number of extranodal sites and the above mentioned two groups. The relative risk for death was 1.9 for the DLBCL group with abnormal PIK3CA or PTEN (95% CI 1.2-2.9, P ¼ 0.0017) and 2.4 for high-risk IPI group (95% CI 1.4-4.2, Po0.0011).
To our knowledge, this is the first report on the presence of PIK3CA mutations in DLBCL patients. Furthermore, the ability to stratify DLBCL patient outcome based on the deregulation of PIP3 production gives further support of putative role of PI3K pathway in the regulation of DLBCL progression, which makes this pathway an attractive target for pharmacologic interventions. In particular, directed small molecule antagonism of PIK3CA proteins may be an effective measure for the treatment of DLBCL. Altogether, our study shows that a large proportion of DLBCL have either an inactivation of PTEN or activation of PIK3CA and this group is associated with poor overall survival. This loss of PIP3 homeostasis due to PTEN inactivation and PIK3CA activation in DLBCLs is remarkably similar to that reported in other human cancers. These findings indicate that mutation in PIK3CA is likely to function as an oncogene in DLBCL and argue for the role of PIK3CA targeting in the treatment of DLBCL patients.
Hypermethylation of TTC12 gene in acute lymphoblastic leukemia 11q23 may house several genes that are important for the process of leukemogenesis. Structural aberrations involving 11q are among the most common aberrations in a number of hematological malignancies and often harbor a breakpoint at 11q23. 1 One of the common aberrations is deletion, that is associated with a poor clinical outcome. 2 Chromosome deletion suggests that the region might contain at least a tumor suppressor gene important for the genesis of lymphoproliferative disorders. 3, 4 Investigating cancer-specific methylation is a preferential approach for identifying genes that are important in cancer development. 5 There have been few reports regarding methylation involving 11q23 in leukemia. Therefore, we further investigated whether, in leukemia, there exists a gene that is controlled by the epigenetic modification in this region.
We screened several candidate genes on chromosome 11q23, 3 for example, ZW10, NCAM1, ANKK1 and tetratricopeptide repeat (TPR) domain 12 (TTC12), by combined bisulfite
